• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Trends Cardiovasc Med . The Impact of Influenza Vaccination in Patients With Cardiovascular Disease: An Overview of Systematic Reviews

tetano

Editor, Senior Moderator
Trends Cardiovasc Med


. 2020 Jun 11;S1050-1738(20)30082-7.
doi: 10.1016/j.tcm.2020.06.003. Online ahead of print.
The Impact of Influenza Vaccination in Patients With Cardiovascular Disease: An Overview of Systematic Reviews


Barbara S Rodrigues[SUP] 1 [/SUP], Mariana Alves[SUP] 2 [/SUP], Gon?alo S Duarte[SUP] 3 [/SUP], Jo?o Costa[SUP] 3 [/SUP], Fausto J Pinto[SUP] 4 [/SUP], Daniel Caldeira[SUP] 5 [/SUP]



Affiliations

Abstract

Whether influenza vaccination can play a prognostic role in patients with cardiovascular (CV) disease (coronary artery disease (CAD), heart failure, stroke, peripheral artery disease (PAD)) is still not completely well-established. We conducted this overview of systematic reviews (SR) evaluating the effects of influenza vaccination in secondary prevention of CV disease. An electronic search was performed in the MEDLINE (to November 2019). Eligibility criteria included SR evaluating the effect of influenza vaccination in patients with CV disease. The risk of bias of the included systematic reviews was evaluated using the ROBIS tool. All-cause mortality, CV mortality, major adverse cardiovascular events (MACE) and hospitalizations were evaluated. Whenever required, data were recalculated through a random-effects meta-analysis to obtain pooled data for the patients at secondary CV prevention. The search process yielded four SR: two in CAD, one in heart failure and one in stroke. There were no SR evaluating the vaccine in PAD. The risk of bias was unclear (2 SR) and high (2 SR). Influenza vaccination in patients with CAD showed a risk reduction in all-cause mortality (data recalculated), cardiovascular mortality and MACE, particularly in patients with recent acute coronary syndrome. In patients with heart failure, vaccination was associated with a decreased risk of all-cause mortality. There was a non-significant trend in recurrent stroke risk reduction in patients with previous stroke. The available evidence suggests that influenza vaccination was associated with a protective effect in CAD and HF patients. However, these results need to be clarified with higher quality evidence studies.

Keywords: Cardiomyopathy; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary heart disease; Heart failure; Secondary prevention; Stroke; Systematic review.
 
Back
Top Bottom